Diabetes Self-Management Blog

Drug manufacturer Pfizer has changed the labeling on its inhaled insulin, Exubera, to warn that a few cases of lung cancer have occurred in people who have used the product. Although Pfizer announced that it would stop marketing Exubera last year (see "Exubera Inhaled Insulin Discontinued"), it is still available by prescription and is being used by about 4,000 people worldwide.

Data from a clinical trial program for Exubera showed that 6 out of 4,740 people taking Exubera developed lung cancer compared to 1 out of 4,292 people not taking Exubera. One Exubera user who was not part of a clinical trial also reported developing lung cancer. The updated labeling states that all of these people had a prior history of cigarette smoking and that there were not enough cases to determine whether the use of Exubera was related to the development of lung cancer.

In a statement released by Pfizer, Joe Fezcko, M.D., (the company’s Chief Medical Officer) stated that “Physicians should seek alternate treatment options to maintain patients’ glycemic control.” However, in a letter to people taking Exubera as part of an “extended transition program,” Rochelle L. Chaiken, M.D., (Vice President of Global Medical Cardiovascular and Metabolic Disease at Pfizer) advised people not to stop taking Exubera without discussing it with their doctor first.

Pfizer announced that it would cease marketing Exubera in October of 2007, citing poor sales as the reason. Nektar Therapeutics, the company that originally developed Exubera and partnered with Pfizer to market it, announced this month that it was ending its search for a new marketing partner and was moving its business away from inhaled insulin.

Two other pharmaceutical companies that had been developing their own inhaled insulin products have also recently ceased pursuing them: Novo Nordisk and partner Aradigm ended development on their AERx system in January of this year, and Eli Lilly & Co. and partner Alkermes, Inc. dropped their AIR Insulin project in March. A smaller company called MannKind Corp. is continuing to develop its Technosphere Insulin product; data from phase 3 clinical trials (the final round of trials before a new drug is submitted to the FDA for approval) of this product should become available later this year.

POST A COMMENT       
  

Comments
  1. This one I did have trouble believing when I first saw it: a lady inhaling insulin from a large plastic tube. I do not understand why people feel that injections are a problem. Most diabetics I have meet have ample tummy grease which is relatively nerve free compared to fingers. I find finger pricking to be more of a bother. Todays silicone coated fine needles are totally painless or am I just a rare case?

    Posted by CalgaryDiabetic |
  2. The idea of the inhaled insulin is that you can get a more accurate dose and have it in the bloodstream immediately. No absorption time. And no dangerous waste. If this cancer warning is true, it’s too bad.
    David

    Posted by David Spero RN |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of R.A. Rapaport Publishing, Inc., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


Insulin & Other Injected Drugs
Do You Know Your Insulin Level? (10/25/13)
Start With Three Drugs? (07/10/13)
FDA Patient Network Makes Its Debut (06/05/13)
Prescribe Insulin? Nah! Too Much Trouble (05/14/13)

Diabetic Complications
What You Need to Know About UTIs (03/24/14)
Mediterranean Diet Linked to Lower Risk of PAD (02/12/14)
Don't Call My Liver Fat! (12/16/13)
Neuropathy Common in Young Adults (12/13/13)

Diabetes News
Overweight People With Type 2 May Benefit From Gastric Banding (04/11/14)
FDA Panel Votes in Favor of Inhalable Insulin; Diet Drug Recalled (04/09/14)
Good News About Good Diabetes Self-Management (03/28/14)
Diabetes Developed at Midlife May Affect Brain Function in Old Age (03/21/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.


Carbohydrate Restriction: An Option for Diabetes Management
Some people find that decreasing the amount of carbohydrate they eat can help with blood glucose control. Here’s what to know about this approach.

Insulin Patch Pumps: A New Tool for Type 2
Patch pumps are simpler to operate than traditional insulin pumps and may be a good option for some people with Type 2 diabetes who need insulin.

How Much Do You Know About Vitamins?
Learn what these micronutrients can and can’t do for you.

Complete table of contents
Get a FREE ISSUE
Subscription questions